Factor Xa Inhibitors
Antistasin-family anticoagulants targeting the coagulation cascade convergence point
Last updated: March 14, 2026
Mechanism Disclaimer
Factor Xa occupies a uniquely strategic position in the coagulation cascade — it sits at the convergence of the intrinsic and extrinsic pathways, and a single molecule of Factor Xa generates approximately 1,000 molecules of thrombin through the prothrombinase complex. Leech-derived Factor Xa inhibitors (FXaI) belong to the antistasin superfamily and provided conceptual validation that ultimately led to the oral Factor Xa inhibitor drug class.
Molecular Properties
| Form | MW | Ki (Amidolytic) | Ki (Prothrombinase) | Note |
|---|---|---|---|---|
| Native FXaI | 13–14 kDa (85 aa) | ~1 pM | 72–120 nM | Isolated from SGS; limited supply |
| Recombinant FXaI (r-FXaI) | 14.4 kDa (133 aa) | ~10 nM | ~0.04 nM | Superior prothrombinase inhibition |
FXaI belongs to the antistasin superfamily with approximately 50% sequence homology to antistasin from Haementeria officinalis. The native form (85 amino acids, 13–14 kDa) is smaller than the recombinant construct (133 amino acids, 14.4 kDa), which includes additional sequence for improved expression and stability.
Preclinical Superiority
r-FXaI vs. Heparin
Zeelon et al. (1997) demonstrated that recombinant FXaI was superior to heparin in animal thrombosis models. r-FXaI achieved greater antithrombotic efficacy with less bleeding risk — a therapeutic index advantage attributable to selective Factor Xa inhibition versus heparin’s broad antithrombin-mediated mechanism. Notably, r-FXaI showed dramatically improved prothrombinase complex inhibition (Ki ~0.04 nM) compared to the native form, suggesting the recombinant construct better mimics the physiological inhibitory conformation.
Pharmaceutical Legacy — Oral Factor Xa Inhibitors
The conceptual pathway from leech FXaI to the modern Factor Xa inhibitor drug class represents one of the clearest bench-to-bedside translations in zoopharmacology. Leech antistasin research validated Factor Xa as a druggable target, leading to the development of oral small-molecule inhibitors that now represent the dominant oral anticoagulant market.
| Drug | FDA | Indication | Mechanism |
|---|---|---|---|
| Rivaroxaban (Xarelto) | 2011 | DVT/PE, stroke prevention in AF, post-surgical prophylaxis | Direct, reversible FXa active-site inhibitor |
| Apixaban (Eliquis) | 2012 | Stroke prevention in AF, DVT/PE treatment and prophylaxis | Direct, reversible FXa active-site inhibitor |
| Edoxaban (Savaysa) | 2015 | Stroke prevention in AF, DVT/PE treatment | Direct, reversible FXa active-site inhibitor |
LCI — Carboxypeptidase B Inhibitor
Maintaining Fibrinolytic Susceptibility
LCI (Leech Carboxypeptidase Inhibitor) is a companion anticoagulant molecule that targets thrombin-activatable fibrinolysis inhibitor (TAFI). TAFI normally removes C-terminal lysine residues from partially degraded fibrin, reducing plasminogen binding and slowing clot lysis. By inhibiting TAFI-mediated carboxypeptidase B activity, LCI maintains fibrinolytic susceptibility of the clot — synergizing with destabilase’s direct fibrinolytic action and hirudin’s prevention of TAFI activation.
Antistasin Superfamily
The antistasin superfamily — named after antistasin from Haementeria officinalis — includes multiple leech-derived inhibitors sharing a conserved cysteine-rich scaffold with characteristic disulfide bonding patterns. Members include FXaI, bdellastatin (bdellin A), and hirustasin. The superfamily represents one of the most pharmaceutically productive structural families in zoopharmacology, having contributed to the conceptual validation of both the Factor Xa inhibitor and direct thrombin inhibitor drug classes.
Related Resources
Decorsin & Ornatin
RGD-containing antiplatelet peptides from New World leeches.
Learn more →
Hirudin-Like Factors
Thrombin inhibitors with femtomolar affinity.
Learn more →
Direct Thrombin Inhibitors
The DTI drug class from hirudin to dabigatran.
Learn more →
Compound Reference
Complete SGS bioactive component database.
Learn more →